Skip to content

EBITDA at other companies

Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-$14.44M+0.2%
Enovis logo
EnovisENOV
$79.89M+224%
SI-BONE, Inc. logo
SI-BONE, Inc.SIBN
-$3.48M+44.0%
Stryker logo
StrykerSYK
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Calculated from Bioventus’s reported figures.

$8.4Mebit+
$11.2MDepreciation Depletion & Amortization
=$19.62M

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's EBITDA?
Bioventus (BVS) reported EBITDA of $19.62M in Q1 2026.
How has Bioventus's EBITDA changed year-over-year?
Bioventus's EBITDA increased by 17.3% year-over-year, from $16.73M to $19.62M.
What is the long-term trend for Bioventus's EBITDA?
Over 3 years (2022 to 2025), Bioventus's EBITDA has grown at a -3.3% compound annual growth rate (CAGR), from -$111.84M to $100.99M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.